Zwarthoff E - Search Results

1

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years.

Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, Fine SW, Humphrey PA, Dehner LP, Amin MB, Rüschoff J, Boltze C, Tannapfel A, Zwarthoff E, Lopez-Beltran A, Montironi R, Langner C, Stoehr R, Hartmann A, Giedl J. Weyerer V, et al. Among authors: zwarthoff e. J Cancer. 2017 Feb 5;8(3):323-331. doi: 10.7150/jca.17482. eCollection 2017. J Cancer. 2017. PMID: 28261332 Free PMC article.

2

E-cadherin expression determines the mode of replacement of normal urothelium by human bladder carcinoma cells.

Rebel JM, Thijssen CD, Vermey M, Delouvée A, Zwarthoff EC, Van der Kwast TH. Rebel JM, et al. Among authors: zwarthoff ec. Cancer Res. 1994 Oct 15;54(20):5488-92. Cancer Res. 1994. PMID: 7923182

3

An in vitro model of intra-epithelial expansion of transformed urothelial cells.

Rebel JM, de Boer WI, Thijssen CD, Vermey M, Zwarthoff EC, van der Kwast TH. Rebel JM, et al. Among authors: zwarthoff ec. Int J Cancer. 1993 Jul 9;54(5):846-50. doi: 10.1002/ijc.2910540520. Int J Cancer. 1993. PMID: 8325710

4

Loss of heterozygosity on chromosome 9 and loss of chromosome 9 copy number are separate events in the pathogenesis of transitional cell carcinoma of the bladder.

Van Tilborg AA, Hekman AC, Vissers KJ, van der Kwast TH, Zwarthoff EC. Van Tilborg AA, et al. Among authors: zwarthoff ec. Int J Cancer. 1998 Jan 5;75(1):9-14. doi: 10.1002/(sici)1097-0215(19980105)75:1<9::aid-ijc2>3.0.co;2-1. Int J Cancer. 1998. PMID: 9426683

5

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.

van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. van Rhijn BW, et al. Among authors: zwarthoff ec. Cancer Res. 2001 Feb 15;61(4):1265-8. Cancer Res. 2001. PMID: 11245416

6

Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial.

van Rhijn BW, Lurkin I, Kirkels WJ, van der Kwast TH, Zwarthoff EC. van Rhijn BW, et al. Among authors: zwarthoff ec. Cancer. 2001 Aug 15;92(4):768-75. doi: 10.1002/1097-0142(20010815)92:4<768::aid-cncr1381>3.0.co;2-c. Cancer. 2001. PMID: 11550146

7

Frequent FGFR3 mutations in urothelial papilloma.

van Rhijn BW, Montironi R, Zwarthoff EC, Jöbsis AC, van der Kwast TH. van Rhijn BW, et al. J Pathol. 2002 Oct;198(2):245-51. doi: 10.1002/path.1202. J Pathol. 2002. PMID: 12237885

8

Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine.

van Rhijn BW, Lurkin I, Chopin DK, Kirkels WJ, Thiery JP, van der Kwast TH, Radvanyi F, Zwarthoff EC. van Rhijn BW, et al. Clin Cancer Res. 2003 Jan;9(1):257-63. Clin Cancer Res. 2003. PMID: 12538478

9

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.

van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER, Jöbsis AC, Zwarthoff EC. van Rhijn BW, et al. Cancer Res. 2004 Mar 15;64(6):1911-4. doi: 10.1158/0008-5472.can-03-2421. Cancer Res. 2004. PMID: 15026322 Free article.

10

Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.

van Oers JM, Adam C, Denzinger S, Stoehr R, Bertz S, Zaak D, Stief C, Hofstaedter F, Zwarthoff EC, van der Kwast TH, Knuechel R, Hartmann A. van Oers JM, et al. Int J Cancer. 2006 Sep 1;119(5):1212-5. doi: 10.1002/ijc.21958. Int J Cancer. 2006. PMID: 16570285

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

236 results

Search Page

Filters